Intratumoral Infection with Murine Cytomegalovirus Synergizes with PD-L1 Blockade to Clear Melanoma Lesions and Induce Long-term Immunity.

PubWeight™: 0.76‹?›

🔗 View Article (PMID 27434584)

Published in Mol Ther on June 10, 2016

Authors

Dan A Erkes1, Guangwu Xu2, Constantine Daskalakis3, Katherine A Zurbach1, Nicole A Wilski1, Toktam Moghbeli1, Ann B Hill2, Christopher M Snyder1

Author Affiliations

1: Department of Microbiology and Immunology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
2: Department of Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, Oregon, USA.
3: Division of Biostatistics, Department of Pharmacology & Experimental Therapeutics, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.

Articles cited by this

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79

Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol (2012) 12.19

T cell exhaustion. Nat Immunol (2011) 11.08

Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature (2011) 9.30

Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med (2009) 7.33

Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med (2013) 4.86

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol (2015) 4.85

Systematic excision of vector sequences from the BAC-cloned herpesvirus genome during virus reconstitution. J Virol (1999) 4.23

Evolutionary struggles between NK cells and viruses. Nat Rev Immunol (2008) 3.79

Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988-2004. Clin Infect Dis (2010) 3.61

Evasion of CD8+ T cells is critical for superinfection by cytomegalovirus. Science (2010) 3.31

Immune clearance of highly pathogenic SIV infection. Nature (2013) 3.15

Epidermal growth factor receptor is a cellular receptor for human cytomegalovirus. Nature (2003) 2.77

Epidermal injury and infection during poxvirus immunization is crucial for the generation of highly protective T cell-mediated immunity. Nat Med (2010) 2.61

Immediate-early genes of murine cytomegalovirus: location, transcripts, and translation products. J Virol (1987) 2.30

Going viral with cancer immunotherapy. Nat Rev Cancer (2014) 2.27

Evolution of diverse antiviral CD8+ T cell populations after murine cytomegalovirus infection. Eur J Immunol (2005) 2.12

Human cytomegalovirus envelope glycoproteins B and H are necessary for TLR2 activation in permissive cells. J Immunol (2006) 2.12

Tumor masses support naive T cell infiltration, activation, and differentiation into effectors. J Exp Med (2010) 1.97

Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol (2012) 1.90

Therapeutic cancer vaccines: are we there yet? Immunol Rev (2011) 1.86

Enrichment of immediate-early 1 (m123/pp89) peptide-specific CD8 T cells in a pulmonary CD62L(lo) memory-effector cell pool during latent murine cytomegalovirus infection of the lungs. J Virol (2000) 1.81

Tumor-associated macrophages as major players in the tumor microenvironment. Cancers (Basel) (2014) 1.74

New viruses for cancer therapy: meeting clinical needs. Nat Rev Microbiol (2013) 1.72

Genome-wide analysis reveals a highly diverse CD8 T cell response to murine cytomegalovirus. J Immunol (2006) 1.67

Human cytomegalovirus induces monocyte differentiation and migration as a strategy for dissemination and persistence. J Virol (2004) 1.66

Expansion of protective CD8+ T-cell responses driven by recombinant cytomegaloviruses. J Virol (2004) 1.55

Activation of EGFR on monocytes is required for human cytomegalovirus entry and mediates cellular motility. Proc Natl Acad Sci U S A (2009) 1.51

Molecular profiling of cytomegalovirus-induced human CD8+ T cell differentiation. J Clin Invest (2010) 1.50

Transcriptome analysis reveals human cytomegalovirus reprograms monocyte differentiation toward an M1 macrophage. J Immunol (2008) 1.48

Late-phase expression of a murine cytomegalovirus immediate-early antigen recognized by cytolytic T lymphocytes. J Virol (1986) 1.48

Role for TLR2 in NK cell-mediated control of murine cytomegalovirus in vivo. J Virol (2006) 1.35

CD8(+) T-cell attenuation of cutaneous herpes simplex virus infection reduces the average viral copy number of the ensuing latent infection. Immunol Cell Biol (2008) 1.29

Design of agonistic altered peptides for the robust induction of CTL directed towards H-2Db in complex with the melanoma-associated epitope gp100. Cancer Res (2009) 1.26

Human CMV infection of endothelial cells induces an angiogenic response through viral binding to EGF receptor and beta1 and beta3 integrins. Proc Natl Acad Sci U S A (2008) 1.25

Population analysis of antiviral T cell responses using MHC class I-peptide tetramers. Clin Exp Immunol (2003) 1.25

Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res (2014) 1.24

Processing and presentation of murine cytomegalovirus pORFm164-derived peptide in fibroblasts in the face of all viral immunosubversive early gene functions. J Virol (2002) 1.19

Oncolytic viruses as anticancer vaccines. Front Oncol (2014) 1.13

Cytomegalovirus-induced effector T cells cause endothelial cell damage. Clin Vaccine Immunol (2012) 1.02

Viral vector-based therapeutic cancer vaccines. Cancer J (2011) 1.00

Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapy. Oncotarget (2015) 0.99

Human cytomegalovirus infection of M1 and M2 macrophages triggers inflammation and autologous T-cell proliferation. J Virol (2012) 0.99

Cytomegalovirus-based cancer vaccines expressing TRP2 induce rejection of melanoma in mice. Biochem Biophys Res Commun (2013) 0.94

Cytomegalovirus hijacks CX3CR1(hi) patrolling monocytes as immune-privileged vehicles for dissemination in mice. Cell Host Microbe (2014) 0.94

The context of gene expression defines the immunodominance hierarchy of cytomegalovirus antigens. J Immunol (2013) 0.94

Use of bacterial artificial chromosomes in generating targeted mutations in human and mouse cytomegaloviruses. Curr Protoc Immunol (2007) 0.94

A cytomegalovirus-based vaccine expressing a single tumor-specific CD8+ T-cell epitope delays tumor growth in a murine model of prostate cancer. J Immunother (2012) 0.92

Systemic hematogenous maintenance of memory inflation by MCMV infection. PLoS Pathog (2014) 0.90

Cytomegalovirus-Based Vaccine Expressing a Modified Tumor Antigen Induces Potent Tumor-Specific CD8(+) T-cell Response and Protects Mice from Melanoma. Cancer Immunol Res (2015) 0.86

Competition for antigen at the level of the APC is a major determinant of immunodominance during memory inflation in murine cytomegalovirus infection. J Immunol (2013) 0.85

Control of murine cytomegalovirus infection by γδ T cells. PLoS Pathog (2015) 0.85

Competition between T cells maintains clonal dominance during memory inflation induced by MCMV. Eur J Immunol (2013) 0.84

Murine CMV Infection Induces the Continuous Production of Mucosal Resident T Cells. Cell Rep (2015) 0.82

Resolving the titer of murine cytomegalovirus by plaque assay using the M2-10B4 cell line and a low viscosity overlay. Virol J (2014) 0.81

Microvessel origin and distribution in pulmonary metastases of B16 melanoma: implication for adoptive immunotherapy. Cancer Res (1995) 0.80

Intratumoral immunotherapy for melanoma. Cancer Immunol Immunother (2015) 0.79

Cancer vaccines: Trafficking of tumor-specific T cells to tumor after therapeutic vaccination. Int J Biochem Cell Biol (2014) 0.78